4 RESULTS
COMMENT Elenbecestat trial starts with hope and elan We were pleased to hear that elenbecestat (Eisai/Biogen) has passed Phase 2 trials with no apparent toxicity and successful changes in “pathology”—although not in actual cognitive symptoms. Several candidate ...
COMMENT A BACE1 inhibitor failure is an opportunity for selective BACE1 inhibition. Janssen recently announced that it terminated atabecestat development. The announcement further stated that serious elevations in liver enzymes were detected in some patients ...
COMMENT Merck pushing forward on clinical trials for a BACE1 inhibitor in such late stages of AD is certainly puzzling, as others have already noted. It is to be expected that, once Aβ has plateaued and sufficient Aβ-related damage has been done, there will be ...
COMMENT Comment by Debomoy Lahiri and Bryan Maloney The previously proposed LEARn (Latent Early-life Associated Regulation) pathway may explain the recently featured results from Chumley and Kahn and from Knuessel et al. regarding infection and AD. Work such as ...
